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Abstract
Backgrounds: ANCA-associated vasculitis (AAV) frequently present with a chronic relapsing 
course. Relapse leads to an increased need for therapeutic agents and consequent toxicity. 
Summary: When referring to the available options for the management of AAV, the efficacy 
of glucocorticoids (GCs) is unquestionable. However, similarly unquestionable are their side 
effects. It has been more than 40 years since the efficacy of cyclophosphamide (CYC) as an 
add-on therapy to GCs in the management of necrotizing vasculitis has been proven. At the 
same time, concerns about the devastating side effects related to a prolonged exposure to 
this agent were raised. Despite the well-known side effects, the management of AAV re-
mained centred on CYC until the early 2000s, when the pilot data first supporting the anec-
dotal efficacy of rituximab (RTX) were reported. However, it was not until 2010 that the non-
inferiority of RTX to CYC for remission-induction in AAVs was demonstrated in 2 randomized 
controlled trials. Key Messages: Treatment of AAV has improved over the last decade, and 
currently available strategies are able to induce remission in the majority of the cases. Here-
with, we aim to critically review available evidence and to critically address the following ques-
tion: How can we reduce the GCs use the management of patients with AAV? Novel strategies 
that avoid the toxicity associated with currently used agents should be the goal. Ideally, these 
approaches should be GC-free. © 2020 The Author(s)
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Introduction
ANCA-associated vasculitis (AAV) frequently present with a chronic relapsing course. 
Relapse leads to an increased need for therapeutic agents and consequent toxicity. When 
referring to the available options for the management of AAV, the efficacy of glucocorticoids 
(GCs) is unquestionable. However, similarly unquestionable are their side effects.
It has been  more than 40 years  since Fauci et al. [1] proved the efficacy of cyclophos-
phamide (CYC) as an add-on therapy to GCs in the management of necrotizing vasculitis. 
While they demonstrated the efficacy of the CYC in addition to GCs in inducing remission also 
in the most severe cases, at the same time, concerns about the devastating side effects related 
to a prolonged exposure to this protocol were raised. Since then, a tremendous body of 
research has been conducted to find alternative agents to GCs for the management of AAV. In 
regards to the use of immunosuppressants, the research efforts were aiming at optimizing 
available protocols, to decrease the cumulative dose of cytotoxic agents such as CYC, and to 
guide the switching from an oral to an intravenous pulsed to reduce prolonged toxicity [2]. 
However, the constant unmet need was to identify protocols with a satisfactory efficacy and 
safety profile paralleled by a steroid-sparing effect and incorporate them in remission-main-
tenance regimens in order to taper GCs more rapidly while at the same time reduce the risk 
of relapse.
Despite the well-known side effects, the management of AAV remained centred on CYC 
until the early 2000s, when the pilot data first supporting the anecdotal efficacy of rituximab 
(RTX) were reported [3]. However, it was not until 2010 that the non-inferiority of RTX to 
CYC for remission-induction in AAVs was demonstrated in 2 randomized controlled trials 
(RCTs) (RAVE [4] and RITUXVAS [5]). Nevertheless, although the 2 RCTs have demonstrated 
RTX to be the most effective induction therapy in patients with relapsing disease, the optimal 
treatment duration and RTX dose are still discussed. Similarly, the debate whether to admin-
ister a maintenance dose to every patient, at a fixed time interval or on the basis of B-cell 
count and ANCA titre or only when disease manifestations do occur is currently ongoing.
Two subsequent RCTs (MAINRITSAN [6] and MAINRITSAN2 [7]) investigated the efficacy 
of RTX in remission maintenance. The main characteristics of the RTCs investigating the use 
of RTX are summarized in Table 1. The MAINRITSAN study showed a superiority of RTX given 
in 6 fixed-schedule monthly infusion over azathioprine (AZA) in reducing the rate of major 
relapse. A further benefit of RTX was also observed when analysing physical abilities and 
quality of life [8]. Conversely, an individually tailored RTX administration was investigated in 
the MAINRITSAN2. When monitoring patients every 3 months, cases were given RTX in the 
presence of disease reactivation, namely, peripheral B-cell repopulation or the increase of 
ANCA titres. Controls received a fixed 500 mg RTX on a pre-fixed protocol on days 0 and 14 
post-randomization, then 6, 12, and 18 months after the first infusion. The main findings of 
this study rely on the observation that relapse rates did not differ significantly between indi-
vidually tailored and fixed-schedule RTX regimens. However, patients in individually tailored-
arm received fewer RTX infusions. The MAINRITSAN3 is currently ongoing (clinicaltrials.gov 
#NCT02433522). The investigators aim to conduct a randomized placebo-controlled trial of 
a long-term RTX maintenance treatment (46 months) against a conventional maintenance 
treatment (18 months).
The recruitment of a further study, the RITAZAREM (clinicaltrials.gov #NCT01697267), 
has been recently listed as completed and results are highly expected (clinicaltrials.gov 
#NCT02433522). This RTCs recruited AAV patients at the time of relapse, all receiving 4 
weekly infusion of RTX at the dose of 375 mg/m2 and GCs. After 4 months, in case remission 
is achieved, further treatment with RTX (a single dose over 4 months for 2 years) or AZA will 
be chosen randomly. The patients will be followed for 4 years.
3Kidney Blood Press Res
Fenoglio et al.: Rituximab for ANCA Vasculitis
www.karger.com/kbr
© 2020 The Author(s). Published by S. Karger AG, BaselDOI: 10.1159/000509608
Several other regimens exploring the use of RTX as a maintenance agent have explored 
over the last years, to include protocol with low-dose RTX in patients with limited forms of 
granulomatosis with polyangiitis [9]. When taken together the above mentioned data, while 
the efficacy of RTX seems consistent across the studies, a main question remains unanswered: 
How can we reduce the GCs use the management of patients with AAV?
In fact, patients included in the main RCTs to investigate the efficacy of RTX were exposed 
to similar overall doses of GCs. Furthermore, reducing the use GCs especially in the mainte-
nance phase might pose some concerns in the treating physicians.
The REMAIN trial [10] was a prospective randomized trial to compare 2 different dura-
tions of maintenance immunosuppressive therapy for the prevention of relapse in AAV. 
Patients with AAV who were in stable remission after CYC/GCs-based induction followed by 
AZA/GCs maintenance therapy were randomized (1:1) to receive continued AZA/GCs for 48 
months (continuation group) or to withdraw AZA/GCs by 24 months (withdrawal group). 
They found a 2-fold increase in the risk of relapse in the withdrawal group and a reduced 
renal survival in AAV when compared to the continuation group.
The CLEAR trial pioneered the search for GC-free regimen in the management of AAV. 
They aimed at investigating if avacopan (CCX168), an orally administered, selective C5a 
receptor inhibitor, could replace oral GCs without impacting efficacy. Newly diagnosed or 
Table 1. Main characteristics of randomized controlled trials investigating the use of RTX in AAV
Study Protocol GCs
RAVE [4] RTX group:
RTX 375 mg/m2 once weekly for 4 weeks plus daily 
placebo-CYC.
Control group:
Placebo-RTX infusions plus daily CYC (2 mg/kg, adjusted  
for renal insufficiency)
One to 3 pulses of MP (1,000 mg each), followed by 
P at a dose of 1 mg/kg/day. The dose was tapered so 
that by 5 months, all patients who had a remission 
without disease flares had discontinued GCs
RITUXIVAS [5] RTX group:
RTX 375 mg/m2 IV × 4 once weekly for 4 weeks plus CYC  
15 mg/kg IV × 2
CYC group:
IV CYC 15 mg/kg IV × 2 (minimum 3 months, maximum  
6 months)
IV MP (at a dose of 1 g) followed by P (1 mg/kg/day 
initially, with a reduction to 5 mg/day at the end of  
6 months)
MAIN 1 [6] RTX (arm A):
RTX infusion will be performed at D1, D15, M6, M12, and 
M18 (i.e., a total of 5 infusions), at the dose of 500 mg at  
a fixed dosage
AZA (arm B):
AZA (2 mg/kg/day) for 12 months, then progressively 
tapered until its discontinuation at month 22
P (or equivalent) at a dose of 1 mg/kg/day with 
gradual tapering according to a regimen adjusted to 
body weight over a mean of 18 months since 
diagnosis
MAIN 2 [7] RTX (arm A):
RTX infusion at D1, D15, M6, M12, and M18 (i.e., a total of  
5 infusions), at the dose of 500 mg at a fixed dosage
RTX (arm B):
RTX infusion at D1 and then ANCA status and CD19+ 
lymphocyte count monitored every 3 months. Patients 
received new 500 mg RTX infusions either if CD19 were  
> to 0/mm3 or if ANCA are positive again or if ANCA titre 
significantly raised
P (or equivalent) 1 mg/kg/day with gradual 
tapering according to a regimen adjusted to body 
weight over a mean of 18 months since diagnosis
AAV, ANCA-associated vasculitis; GCs, glucocorticoid; RTX, rituximab; CYC, cyclophosphamide; MP, methylprednisolone; P, pred-
nisone; AZA, azathioprine; PTS, patients; D, day; M, month.
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relapsing AAV patients were randomized to received placebo plus prednisone starting at 60 
mg daily (control group), avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 
mg daily), or avacopan (30 mg, twice daily) without prednisone. All patients received CYC or 
RTX. With a primary efficacy end point of treatment response at week 12 (defined as a BVAS 
decrease from baseline of at least 50% plus no worsening in any body system), they concluded 
that avacopan was effective in replacing high-dose GCs in the management of AAV. A double-
blind, active-controlled, phase 3 trial is currently ongoing [11].
More recently, a reduced-dose GCs regimen was tested in patients with end-organ damage 
in the lately published PEXIVAS [12] trial. The study sought to determine whether patients 
with severe renal impairment and/or pulmonary haemorrhage at disease onset benefited 
from the addition of plasmapheresis to a standard remission-induction regimen (as was 
suggested by the MEPEX [13] trial) either with a standard or reduced-dose GCs regimen. 
While the study showed that plasmapheresis did not add any benefit in terms of risk reduction 
of hard outcomes (death or ESRD), the reduced-dose GCs arm achieved the same efficacy as 
the standard-dose arm with fewer serious infections.
In order to participated in this debate, we have previously reported the encouraging 
results of 11 patients with refractory AAV treated with a “4 + 2” RTX protocol [14, 15]. In 81% 
of the patients, RTX was given due to lack of response or occurrence of side effects after 
treatment with CYC. The “4 + 2” protocol (so called improved protocol [14, 15]) showed a 
good safety profile and its efficacy was confirmed also in a long-term observational study. In 
detail, after a mean follow-up of 85 months since the “4 + 2” RTX protocol, 37% of the patients 
(1 eosinophilic granulomatosis with polyangiitis and 3 microscopic polyangiitis, all MPO-
positive) achieved persistent remission after 1 cycle of “4 + 2” RTX protocol with no further 
relapse observed after up to 108 months. After a median time of more 4 years, 7 out of 11 
patients suffered from a relapse and they were re-treated with RTX (again as monotherapy 
with the same protocol). Following reinduction, they again achieved a complete response 
which was maintained up to 96 months of observation. The strengths of the “4 + 2” approach 
in the management of the most severe case/refractory cases of AAV relies on the sustained 
clinical remission without immunosuppressive maintenance therapy and a negligible dose of 
prednisone since the 5th months.
We recently introduced a therapeutic algorithm combing both clinical and histological 
features to guide AAV management. On the basis of our previous positive experience in 
patients with severe lupus nephritis [16], in AAV patients with serum Cr (sCr) levels higher 
than 5 mg/dL and >50% epithelial (florid) crescents at the renal biopsy (so called “crescentic 
forms”) the “4 + 2” RTX protocol was implemented with 2 pulse (2 weeks apart) of 15 mg/kg 
CYC, adjusted for the renal impairment, in order to potentiate the CD20+ B-cells depletion. 
This intensive B-cell depletion therapy (IBCDT) protocol has been already applied to 12 
severe patients with microscopic polyangiitis (mean sCr 5.8 mg/dL). After a mean obser-
vation time of >1 year, 8 patients (3 with >50% and 5 with <50% florid crescents, including 
1 case having >50% glomerular sclerosis) were haemodialysis-free and in clinical remission. 
All 4 patients with granulomatosis with polyangiitis achieved a complete response of with 
resolution of systemic symptoms.
Histological features of striking renal response obtained with the RTX-based protocols in 
our cohort and clinical points of interest are highlighted in Figures 1 and 2. Subjects have 
given their written informed consent to publish their case. Data collection has been conducted 
according to the Italian regulation on rare diseases.
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Case 1
A 58-year-old woman had a renal biopsy due to sub-nephrotic proteinuria and micro-
scopic haematuria combined with elevated cANCA levels and bilateral lung thickenings. 
Biopsy revealed a necrotizing vasculitis with associated endo- and extra-proliferative 
glomerulonephritis. The picture shows a glomerulus with segmental epithelial crescent 
with an area of fibrinoid necrosis (Fig. 1A), and a glomerulus with circumferential epithelial 
crescent (Fig. 1B). The patient was given corticosteroids and oral CYC for 6 months followed 
by AZA for 3 years with resolution of urinary abnormalities and lung lesions, and serologic 
normalization. Nine years later, the patient had a renal relapse with sub-nephrotic 
proteinuria and renal impairment (with serum Cr of 2.4 mg/dL) and new cANCA elevation. 
She was administered a single cycle of IBCDT consisting of RTX 375 mg/sm given weekly 4 
times with 2 more infusions 1 and 2 months later, combined with 2 infusions of 10 mg/kg 
of cyclophosphamide, and 3 pulses of 1 g of methylprednisolone followed by prednisone 0.8 
mg/kg tapered to 5 mg in 3 months. The IBCDT achieved a disappearance of proteinuria 
and a decrease in serum Cr to 1.5 mg/dL. No further immunosuppressive therapy was 
administered. Five years later, the patient presented with 1 g/day proteinuria, increased 
inflammation parameters and cANCA titre.  The possibility of a new relapse was investi-
gated with a new biopsy. Apart from global sclerosis in 30% glomeruli, and mild signs of 
arteriolosclerosis, renal parenchyma was found to be substantially normal. The picture 
Fig. 1. The picture shows a glomerulus with segmental epithelial crescent with an area of fibrinoid necrosis 
(A) and a glomerulus with circumferential epithelial crescent (B). On her second biopsy and after treatment 
with IBCDT, we found only mild arterial intimal fibrosis (C), while glomeruli had no signs of crescent forma-
tion in Bowman’s space (D). IBCDT, intensive B-cell depletion therapy.
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shows only mild arterial intimal fibrosis (Fig. 1C), while glomeruli had no signs of crescent 
formation in Bowman’s space (Fig. 1D).
The patient was given GCs and oral CYC for 6 months followed by AZA for 3 years with 
resolution of urinary abnormalities and lung lesions and serologic normalization. Nine years 
after the diagnosis, the patient suffered from a renal relapse with sub-nephrotic proteinuria 
and renal functional impairment. She was administered a single cycle of the IBCDT followed 
by prednisone 0.8 mg/kg tapered to 5 mg in 3 months. This case emphasizes the critical role 
of renal biopsy in discriminating between a renal relapse and the appearance of proteinuria 
as a consequence of glomerular sclerosis and parenchymal adaptation following resolution 
of the inflammatory process.
Case 2
This is a 62-year-old male with a necrotizing pauci immune glomerulonephritis with 
>50% of crescents, presenting with acute kidney injury (serum Cr 9 mg/dL and oliguria), mild 
pulmonary thickenings, extremely high anti-MPO ANCA levels, a severe peripheral neuropathy, 
and BVAS score 23. He was successfully treated with the IBCDT. The picture shows a glom-
erulus with a florid circumferential crescent (Fig. 2A) and an extensive lymphocyte inter-
Fig. 2. The picture shows a glomerulus with a florid circumferential crescent (A), and an extensive lympho-
cyte interstitial infiltrate surrounding crescentic glomeruli (B). The second biopsy revealed 20% of global 
glomerular sclerosis without signs of proliferation. The picture shows a normal glomerulus (C) and signs of 
interstitial fibrosis with a sclerotic glomerulus (D).
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stitial infiltrate surrounding crescentic glomeruli (Fig. 2B). In order to define the need of a 
maintenance immunosuppressive therapy, the patient was re-biopsied 6 months later when 
presenting with 1.5 mg/dL of serum Cr, <0.5 g/day proteinuria, mild lung interstitial fibrosis, 
and remarkable improvement of electromyography. BVAS score was 3. The biopsy revealed 
20% of global glomerular sclerosis without signs of proliferation. The picture shows a normal 
glomerulus (Fig. 2C), and signs of interstitial fibrosis with a sclerotic glomerulus (Fig. 2D).
This case again emphasizes the role of renal biopsy in the management of ANCA vasculitis 
patients. Renal biopsy may be decisive in doubtful cases, and it is likely to be much less risky 
than an unneeded immunosuppressive therapy (especially if prolonged like a remission 
maintenance).
What can we learn from these cases? While reducing the exposure to toxic drugs and 
limiting the use of GCs remain among the main unmet needs in the field of AAV, one cannot 
forget that the identification of novel biomarkers or prognostic factors is still warranted. 
More critically, integrating biomarkers in the therapeutic strategies will pave the way for 
tailored treatment. When focussing on risk factors for relapses, for instance, several studies 
have demonstrated that the relapse rate is higher in patients with PR3-AAV when compared 
to MPO-AAV. Similarly, PR3-ANCA has been reported as an independent risk factor for renal 
outcomes in various analyses, albeit some degree of discrepancy among prospective and 
retrospective data still exists [17–19]. In our previously mentioned long-term experience, we 
observed that all 4 patients relapsing in the first 5 years of follow-up after the first “4 + 2” RTX 
cycle were PR3 positive.
Conclusion
Treatment of AAV has improved over the last decade, and currently available strategies 
are able to induce remission in the majority of the cases. Novel strategies that avoid the 
toxicity associated with currently used agents should be the goal. Ideally, these approaches 
should be GCs free. As the AAV are typically characterized by a relapsing course, and in order 
to optimize tailored approaches for the affected patients, physicians should be aware of 
unique features that may influence clinical response.
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